{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 6 of 52', 'Change from baseline for SYN-010 in patient reported', 'outcomes (PRO) using validated questionnaires in the REDCap', 'system.', 'Breath gas area-under-the-curve (AUC) (methane, hydrogen,', 'and hydrogen sulfide) on lactulose breath test at EOS', 'compared to Screening.', 'Spot breath tests at Randomization, Day 28, and Day 56.', 'Comparison of serum cytokine levels at baseline and EOS -', 'measuring for potential immune or inflammatory signals to', 'include the key cytokines of the Th1/Th2/Th17 pathways: IL-2,', 'IL-4, IL-5, IL-9, IL-10, IL-13, IL-17, GM-CSF and IFN-y. Plus TNF-a,', 'IL-12, IL-6, the two chemokines IL-8 and MCP-1, and the gut', 'cytokine IL-25.', 'Microbiome measurements in stool:', 'Bacteria (16S rRNA)', 'Methanogens (qPCR)', 'Study Design', 'Single-center, randomized, double-blind, placebo-controlled clinical', 'trial comprising three periods (Figure 1):', '1.', 'Screening and Pre-treatment Period (up to 17 days prior to the', 'first dose of the study drug),', '2.', 'Treatment Period comprising Randomization (Day 1) and 12', 'weeks of dosing (with clinic visits at Weeks 4, 8, and 12), and', '3. End-of-Study contact between 24 and 48 hours after Week 12', 'for patients who complete the Treatment Period.', 'Figure 1: Clinical study design', 'Screening', 'Treatment Period', 'EOS', 'Pretreatment', 'SYN-010 42 mg q.d. (n=50)', 'SYN-010 21 mg q.d. (n=50)', 'Placebo q.d. (n=50)', '-14', '1', '14', '28', '42', '56', '70', '84', 'Screen', 'Randomize', 'DAY', 'Clinic Visits', 'Breath gases', 'Cytokines in plasma', 'Stool samples for microbiome', 'Main Inclusion Criteria', '1.', 'Male or female participants aged between 18 and 65 years', 'inclusive.']['Date: June 30, 2020', 'Version: 8.0', 'Page: 7 of 52', '2.', 'Patient must be willing and able to participate in the study for', 'the required duration, understand and sign the informed', 'consent form (ICF), and be willing to comply with all protocol-', 'related visits and procedures.', '3.', 'Patient has had IBS-C symptoms (as defined by Rome IV', 'diagnostic criteria) for at least 6 months prior to diagnosis.', '4. Patient has an average score of 3.0 for daily abdominal pain', 'at its worst (11-point numerical rating scale [NRS]) during and', 'up to the 17 days immediately before randomization (i.e. Pre-', 'treatment Period).', '5. Patient has an average of < 3 CSBMs per week or <5 SBMs per', 'week during the 17 days immediately before randomization', '(i.e. Pre-treatment Period).', '6.', 'Patient has a breath methane level 10 ppm on a lactulose', 'breath test administered at Screening.', '7.', 'Patient may be on a stable, continuous regimen of fiber or', 'probiotics one month before the Screening Visit; however, they', 'must maintain a stable dose regimen through Week 12.', '8. Patient must agree to refrain from starting a new diet,', 'changing stable dose of supplemental fiber, or changing', 'exercise pattern that may affect IBS-C symptoms from the time', 'of Screening through the end of the study. If the patient takes', 'food products that are strong inhibitors of cytochrome P450 3A', \"(CYP3A) (e.g. grapefruit juice, Seville orange juice, St. John's\", 'Wort), he/she must agree to refrain from taking these from the', 'time of Screening through the end of the study.', '9.', 'Patient must agree to use an acceptable method of', 'contraception from the time of signing the ICF to 30 days after', 'the final dose of study drug if the patient is a sexually active', 'female of child-bearing potential (defined as any female who', 'has experienced menarche and who is NOT permanently sterile', 'or postmenopausal. Postmenopausal is defined as 12', 'consecutive months with no menses without an alternative', 'medical cause). Adequate contraceptive measures include: oral', 'contraceptives (stable use for two or more cycles before', 'Screening); intrauterine device; Depo-Provera\u00ae; Norplant', 'System implants; partner with a vasectomy; double-barrier', 'birth control (e.g. use of a condom plus diaphragm or condom', 'plus either contraceptive sponge, foam, or jelly); or abstinence.', 'According to drug research standards, male patient must agree', 'to use an acceptable method of contraception and refrain from', 'donating sperm from the time of signing the ICF to 90 days', 'after the final dose of study drug.']\n\n###\n\n", "completion": "END"}